Baseline predictors of vitreomacular adhesion/traction resolution following an intravitreal injection of ocriplasmin

Timothy L. Jackson, Carl D. Regillo, Aniz Girach, Pravin U. Dugel

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

BACKGROUND AND OBJECTIVE: To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA). PATIENTS AND METHODS: Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 μg injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and nonsurgical FTMH closure [month 6]). RESULTS: Younger age, presence of FTMH (odds ratio [OR] = 2.1; 95% confidence interval [CI], 1.1- 3.7), VMA diameter of 1,500 μm or less (OR = 4.9; 95% CI, 2.0-12.4), phakic lens status (OR = 2.8; 95% CI, 1.5-5.2), and absence of epiretinal membrane (OR = 4.1; 95% CI, 2.2-7.9) predicted VMA resolution. FTMHs with apical diameter of 250 μm or less were more likely to close than larger holes (58.3% vs. 24.6%; P = .013). Both FTMH size groups had significantly greater chance of VMA resolution and FTMH closure versus controls. CONCLUSION: Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane.

Original languageEnglish
Pages (from-to)716-723
Number of pages8
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume47
Issue number8
DOIs
StatePublished - Aug 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Baseline predictors of vitreomacular adhesion/traction resolution following an intravitreal injection of ocriplasmin'. Together they form a unique fingerprint.

Cite this